Oncology Hotspot Panel (50 Genes)
Related Gene(s): ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL
Now approved for patients in all 50 states, including New York. Our Oncology Hotspot Panel is designed to detect clinically actionable genetic alterations in patients with advanced solid tumor cancer, typically identified as Stage 2, 3, or metastatic (Stage 4) cancer. In particular, if you are treating advanced melanoma, lung, or colorectal cancer patients, our oncology hotspot assay will provide actionable insights for BRAF variants; specific EGFR variants; and KRAS, BRAF, PIK3CA, and AKT mutant versus wild type reporting (as clinically indicated), in addition to any other clinically-relevant variants detected in the remaining genes.
Using a combination of multiplex PCR and next generation sequencing (NGS) technologies, our Oncology Hotspot assay analyzes 207 regions of the genome to determine if any variants identified are known drivers of cancer and whether any drug response or resistance is associated with the variant(s), providing you with a clear and insightful set of information as part of your overall treatment and care management plan. Hotspot assays, separate from whole exome or whole genome sequencing, look for specific variants within specific regions of the genes being tested versus detecting variants in the entire coding sequence of each gene. This panel currently can be performed on samples for patients residing in any U.S. state, other than New York.
Adult and pediatric patients
- Nine (9) unstained glass slides and one (1) H&E stained glass slide
- Please note: While the Oncology Hotspot assay is designed to detect variants down to 5% allele fraction, we require a tumor specimen submission to contain at least 20% tumor cells to account for tumor heterogeneity
- Ship at room temperature
- 10-21 days
Consent and requisition forms available soon. For additional assistance, please contact us.